Mutation at the HPRT locus in patients with neurocysticercosis treated with Praziquantel

dc.contributor.author	Montero, R
dc.contributor.author	Flisser, A
dc.contributor.author	Madrazo, I
dc.contributor.author	Cuevas, C
dc.contributor.author	Ostrosky Wegman, P
dc.date.accessioned	2011-12-07T13:25:22Z
dc.date.accessioned	2014-01-28T15:17:01Z
dc.date.available	2011-12-07T13:25:22Z
dc.date.available	2014-01-28T15:17:01Z
dc.date.issued	1994
dc.identifier.citation	Montero, R; Flisser, A; Madrazo, I; Cuevas, C; Ostrosky Wegman, P. (1994). Mutation at the HPRT locus in patients with neurocysticercosis treated with Praziquantel. Mutation Reseearch, 305(2), 181-188.
dc.identifier.issn	0921-8262
dc.identifier.uri	http://hdl.handle.net/11154/99957
dc.identifier.uri	10.1016/0027-5107(94)90238-0
dc.identifier.uri	http://hdl.handle.net/11154/174495
dc.description.abstract	Praziquantel (PZQ) is the drug of choice in the treatment of neurocysticercosis (NC), a parasitic disease caused by Taenia solium larvae. Variant frequencies at the hprt locus were analyzed in a group of NC patients before and after treatment with PZQ as well as in two control groups: healthy donors and non-parasitic neurological patients. Data show that PZQ does no induce hprt mutations, but that cysticerci by themselves or together with palliative treatment administered to NC patients could induce mutations in some patients.
dc.language.iso	en
dc.publisher	Mutation Reseearch
dc.subject.classification	468
dc.title	Mutation at the HPRT locus in patients with neurocysticercosis treated with Praziquantel
dc.type	Article
dc.relation.index	WoS